Given the conditions, dysregulated palmitoylation modifications on specific zDHHC enzymes likes zDHHC9, zDHHC13, and zDHHC21 are targeted in AD, HD, schizophrenia, and glioma, suggesting as a therapeutic approach (Liao et al., 2024). This evidence concerns the gene ZDHHC13 and Huntington disease.